Mitapivat: New dawn in pyruvate kinase deficiency and beyond
-
Published:2024-06
Issue:2
Volume:9
Page:101-104
-
ISSN:2468-1245
-
Container-title:Pediatric Hematology Oncology Journal
-
language:en
-
Short-container-title:Pediatric Hematology Oncology Journal
Author:
Khurana RitikaORCID,
Mudaliar Sangeeta
Reference19 articles.
1. Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias;Al-Samkari;Ther Adv Hematol,2021
2. The variable manifestations of disease in pyruvate kinase deficiency and their management;Al-Samkari;Haematologica,2020
3. AG-348 (mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes;Rab;Haematologica,2021
4. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy;Kung;Chem Biol,2012
5. AG348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency;Kung;Blood,2017